Nexcella, A Subsidiary Of Immix Biopharma, Presents 42-Patient Interim Data, With 90% Overall Response Rate In Relapsed Or Refractory Multiple Myeloma At NXC-201 Therapeutic Dose From Its Phase 1 Expansion Trial At The 5th European Car T-Cell Meeting
The poster presents data for 42 patients with relapsed or refractory multiple myeloma who were treated with NXC-201 (formerly HBI0101), of which 29 received the therapeutic dose of 800 million CAR+T cells as of the
